-
Markeder
-
Aksjer
Sustainable finance2025 Euronext ESG Trends ReportLes merA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indekser
Access the white paperInvesting in the future of Europe with innovative indicesLes merThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF-er
The European market place for ETFsEuronext ETF EuropeLes merInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fond
-
Obligasjoner
European Defence BondsGroupe BPCE lists the first bondLes merFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Strukturerte produkter
-
Derivater
Where European Government Bonds Meet the FutureFixed Income derivativesLes merTrade mini bond futures on main European government bonds
-
Råvarer
- Oversikt
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Levering og oppgjør
- Spesifikasjoner og ordninger
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLes merEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressurser
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLes merJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Lytix Biopharma AS: GRANT OF SHARE OPTIONS
18 Apr 2023 16:50 CEST
Utsteder
Lytix Biopharma AS
Oslo, 18. April 2023
The Annual General Meeting of Lytix Biopharma AS (the "Company") has resolved to
grant 360,000 share options in the Company ("Options") under the Company's long
term incentive program.
The following primary insiders of Lytix Biopharma AS have been granted and
allocated Options:
- Marie Roskrow, Chairperson: 60,000 Options
- Marie-Louise Fjällskog, Board member: 60,000 Options
- Brynjar Forbergskog, Board member: 60,000 Options
- Kjetil Hestdal, Board member: 60,000 Options
- Jayson Rieger, Board member: 60,000 Options
- Evelina Vågesjö, Board member: 60,000 Options
The Options are granted without consideration and each Option will upon exercise
give the right to acquire one share in the Company. The exercise price of each
Option is NOK 7.30, which equals to the closing share price of the Company on
Euronext Growth Oslo, on the date of the Notice to Annual General Meeting, 11
April 2023.
The Options will vest gradually pursuant to specific vesting schedules:
- 90,000 Options will vest 12 months after the date of grant, while the
remaining 270,000 Options will vest with 1/36 on the last day of the 36
following months.
Vesting of Options is subject to the Option holder being qualified to be part of
the Company's long term incentive program at each vesting date.
All Options will expire and lapse if not exercised within five years from the
date of grant.
Please refer to the forms appended hereto for the disclosure of Option grants to
primary insiders of the Company.
For further information, please contact:
Gjest Breistein, CFO
Email: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of Communication and Investor Relations
Email: ole.peter.nordby@lytixbiopharma.com
This announcement is made pursuant to section 5-12 of the Norwegian Securities
Trading Act and article 19 of the Market Abuse Regulation.
More information:
Access the news on Oslo Bors NewsWeb site
587883_Notification of Trade - BoD - BF.pdf
587883_Notification of Trade - BoD - MLF.pdf
587883_Notification of Trade - BoD - EV.pdf
587883_Notification of Trade - BoD - JR.pdf
587883_Notification of Trade - BoD - KH.pdf
587883_Notification of Trade - BoD - MR.pdf
Kilde
Lytix Biopharma AS
Leverandør
Oslo Børs Newspoint
Company Name
LYTIX BIOPHARMA AS
ISIN
NO0010405780
Ticker
LYTIX
Marked
Euronext Growth